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Abstract 
Aims 
Molecular investigation of small-cell carcinoma of the ovary, 
hypercalcaemic type (SCCOHT) has revealed that it is a 
monogenetic tumour characterized by alteration of SMARCA4 
(BRG1), encoding a member of the switch/sucrose non-
fermentable (SWI/SNF) chromatin remodelling complex. A 
large majority of cases show loss of expression of the 
corresponding SMARCA4/BRG1 protein. Furthermore, three 
cases of SCCOHT with retained SMARCA4 protein expression 
showed loss of SMARCB1/INI1 expression. The aim of this 
study was to assess the sensitivity and specificity of loss of 
SMARCA4 expression as a diagnostic test for SCCOHT. 
Methods and results 
We performed SMARCA4 and SMARCB1 staining in 245 
tumours, many of which were potentially in the differential 
diagnosis of SCCOHT. We also stained 56 cases of SCCOHT 
for SMARCA4 and 37 of these for SMARCB1. Fifty-four of the 
SCCOHT cases showed complete absence of SMARCA4 
expression. The two cases with retained expression showed 
molecular alteration of SMARCA4. Of the 217 other neoplasms 
with interpretable staining, all retained SMARCA4 expression. 
Although the majority showed diffuse, strong nuclear 
expression, a heterogeneous, typically weak staining pattern 
was present in 13% of cases. All 37 cases of SCCOHT tested 
and all other neoplasms, apart from three malignant rhabdoid 
tumours, showed retained nuclear SMARCB1 expression. Loss 
of SMARCA4 expression had a sensitivity of 96.55% and 
specificity of 100%. 
Conclusions 
Loss of SMARCA4 expression is sensitive and specific for 
SCCOHT. Although some mimics show heterogeneous 
expression, there is retention of nuclear staining in at least a 
part of the tumour; therefore, only complete loss of staining 
should be regarded as being supportive of SCCOHT. 
Introduction 
Small-cell carcinoma of the ovary, hypercalcaemic type 
(SCCOHT) is a rare ovarian tumour that is often associated 
with a very poor outcome. In its original description by Scully, 
the key diagnostic elements were: (i) the presence of small, 
highly mitotic cells with hyperchromatic nuclei and scant 
cytoplasm; (ii) an early age (generally <40 years) of onset; and 
(iii) the presence of hypercalcaemia.[1] In a follow-up study of 
150 cases, the mean age at diagnosis was 23.9 years, but, 
notably, 38% of patients did not have preoperative 
hypercalcaemia. Paradoxically, half of the tumours also 
contained large cells with abundant eosinophilic cytoplasm; 
when these predominate, the tumour is referred to as the 
‘large-cell variant’ of SCCOHT. 
There may be considerable morphological overlap between 
SCCOHT and an array of ovarian and extra-ovarian neoplasms 
of both the small-cell and the large-cell types, such as primary 
and metastatic small-cell neuroendocrine carcinoma, various 
sex cord–stromal tumours (including adult and juvenile 
granulosa cell tumour), various malignant germ-cell tumours, 
endometrial stromal sarcoma, primitive neuroectodermal 
tumour, neuroblastoma, desmoplastic small round-cell tumour, 
undifferentiated carcinoma, malignant lymphoma, and 
malignant melanoma.The diagnostic difficulties are 
compounded by the rarity of SCCOHT and the lack of a specific 
biomarker. In a detailed immunohistochemical analysis of a 
series of these neoplasms, most cases were found to show 
diffuse nuclear positivity with an antibody against the N-
terminus of Wilms tumour 1; although this has some diagnostic 
use, this marker is positive in many other tumours, including 
some in the differential diagnosis of SCCOHT 
Biallelic inactivation of SMARCA4 [encoding a member of the 
switch/sucrose non-fermentable (SWI/SNF) chromatin 
remodelling complex], either through two intra-genic (usually 
exonic) mutations or a single intra-genic mutation and loss of 
heterozygosity (LOH) on chromosome 19p, has recently been 
identified as the defining molecular event in SCCOHT.These 
changes occur in an otherwise stable, diploid genome, and may 
involve the germline DNA. It has been shown that a large 
majority of cases also show loss of expression of the 
corresponding SMARCA4 protein (also referred to as BRG1). 
Furthermore, three cases of SCCOHT with retained SMARCA4 
expression showed loss of expression of SMARCB1 (also 
referred to as INI1), another core member of the SWI/SNF 
complex; one case was found to harbour a frameshift mutation 
in SMARCB1. 
Cognation between SCCOHT, atypical teratoid/rhabdoid 
tumour of the brain and malignant rhabdoid tumour of the 
kidney is suggested by their shared genomics, with all three 
tumours having mutations in SWI/SNF genes (either SMARCA4 
or SMARCB1) in otherwise stable genomes. This molecular 
insight has been epiphanic, revealing their now seemingly 
obvious morphological and clinical similarities (young patients, 
highly aggressive tumours, variable occurrence of 
hypercalcaemia, and occasional hereditary transmission). This 
has led to the proposal that SCCOHT represents a malignant 
rhabdoid tumour of the ovary. 
In the initial articles describing the molecular alterations and in 
subsequent follow-up studies, loss of SMARCA4, or rarely 
SMARCB1, expression has been shown to be highly sensitive 
for SCCOHT, being demonstrated in 109 of 114 (96%, 
including 106 SMARCA4-deficient and three SMARCB1-
deficient) cases (Table 1) (Figure 1).To date, ~3600 cases of 
ovarian (epithelial, sex cord–stromal, and germ-cell), uterine 
(epithelial and stromal) and non-gynaecological tumours have 
been studied (Tables 2 and 3) for SMARCA4 expression, with 
the vast majority of cases showing retained expression. This 
suggests that SMARCA4 is a highly sensitive and specific 
marker for SCCOHT. However, as a broad array of primary and 
considered in the differential diagnosis, it is important to focus 
on the various potential mimics. The previous 
immunohistochemical studies have included limited numbers of 
some of the less common mimics of SCCOHT. We therefore 
aimed to extend prior observations by analysing SMARCA4 
expression in an additional cohort of entities, many of which are 
rare but often considered in the differential diagnosis of 
SCCOHT. We also stained additional cases of SCCOHT for 
SMARCA4, and analysed SMARCB1 expression in a subset of 
the SCCOHT cohort. 
Table 1. Summary of previous and current studies examining 
the immunohistochemical expression of SMARCA4 in cases of 
small-cell carcinoma of the ovary, hypercalcaemic type 
Figure 1.  
A, Small-cell carcinoma of the ovary, hypercalcaemic type; haematoxylin 
and eosin. B, Loss of SMARCA4 expression in small-cell carcinoma of 
the ovary, hypercalcaemic type. Note retained expression in endothelial 
cells and lymphocytes. 
Table 2. SMARCA4 expression in ovarian tumours published 
previously 
Table 3. SMARCA4 expression in uterine epithelial and 
mesenchymal tumours and non-gynaecological tumours 
published previously 
 
Materials and methods 
Case selection and tissue microarray (TMA) 
construction 
Through a multicentre collaboration involving the institutions to 
which the authors are affiliated, 245 potential morphological 
mimics of SCCOHT were collected, together with a range of 
ovarian sex cord–stromal tumours. For the majority of cases, 
TMAs were constructed with duplicate 0.6-mm cores. For those 
cases in which only unstained sections could be obtained, 
whole sections were stained. Included in the survey were 
previously constructed single-core TMAs of neuroblastomas 
(13 cases), Wilms tumours (18 cases), and peripheral 
neuroectodermal tumours (12 cases). Table 4 shows the 
tumour subtypes included in the study cohort. 
Table 4. SMARCA4 expression in tumours other than small-cell 
carcinoma of the ovary, hypercalcaemic type examined in the 
current study 
As a control group, we included 56 cases of SCCOHT, 41 of 
which have been published previously (including both genetic 
and immunohistochemical results).[9, 16] All 56 cases were 
stained with SMARCA4/BRG1, and 37 of these cases, which 
were included in a TMA of SCCOHT, were also stained for 
SMARCB1/INI1. 
Immunohistochemical staining and interpretation 
Four-micrometre sections of TMAs and whole sections were 
processed with the Ventana Discovery Ultra system (Ventana 
Medical Systems, Oro Valley, AZ, USA), with a rabbit 
monoclonal antibody against SMARCA4 (BRG1; ab110641; 
1:25 dilution; Abcam, Cambridge, UK). Cases were stained with 
monoclonal anti-BAF47 (INI1/SMARCB1) antibody (clone 25; 
BD; 1:50 dilution; Transduction Laboratories, San Diego, CA, 
USA). All cases were stained with SMARCA4, and SMARCB1 
staining was performed on all non-SCCOHT cases and on a 
subset of the SCCOHT which include those rare cases with 
retained SMARCA4 expression. The arrays and whole sections 
were scored by two pathologists (B.A.C. and W.G.M.). Any 
nuclear expression of SMARCA4 or SMARCB1 in tumour cells 
was regarded as positive. For a case to be regarded as 
negative (to show loss of staining), there had to be complete 
absence of nuclear staining in tumour cells, together with 
positive nuclear staining of an internal positive control 
(endothelial cells, fibroblasts, or lymphocytes). Cases showing 
absence of staining in both the tumour and the internal controls 
were regarded as uninterpretable. 
Results 
Table 4 summarizes the results of the non-SCCOHT cases. For 
SMARCA4, 217 cases (88.6%) could be interpreted, and all 
showed retained/intact expression. Case attrition was 
predominantly attributable to core drop-out or lack of tumour 
representation, with only one case showing absence of staining 
in internal control cells. One hundred and eighty-nine (87.1%) 
tumours showed diffuse moderate to strong nuclear staining 
with SMARCA4 (Figure 2), whereas 28 (13%) showed 
heterogeneous nuclear staining, usually involving <30% of 
tumour cells; in the majority of the latter cases, staining was 
weak to moderate, with a single tumour showing strong but 
focal staining (Figure 3). Those cases showing heterogeneous 
weak/moderate expression comprised one immature teratoma, 
one mixed germ-cell tumour with predominant choriocarcinoma 
differentiation, three steroid cell tumours, three unclassifiable 
sex cord–stromal tumours, two adult-type granulosa cell 
tumours, one malignant melanoma metastatic to the ovary, one 
lymphoma involving the ovary, one desmoplastic small round-
cell tumour, nine fibromas/fibrothecomas, and five gonads from 
patients with androgen insensitivity syndrome. The single case 
showing strong focal staining was an unclassified sex–cord 
stromal tumour. SMARCB1 staining was intact in all non-
SCCOHT cases, apart from the three malignant rhabdoid 
tumours. 
Fifty-four of the 56 SCCOHT cases showed complete loss of 
SMARCA4 expression (Figure 1). All 37 of the SCCOHT cases 
stained with SMARB1 showed intact nuclear expression. These 
included the two cases with retained SMARCA4 staining. The 
latter two cases did show molecular alteration of SMARCA4, 
and morphologically resembled the other SCCOHT cases. In 
the cohort examined, loss of SMARCA4 expression had a 
sensitivity of 96.55% and a specificity of 100%. 
Figure 2. 
    
A, Ovarian dysgerminoma; haematoxylin and eosin (H&E). B, Strong, 
diffuse nuclear SMARCA4 expression in dysgerminoma. C, Burkitt's 
lymphoma involving the ovary; H&E. D, Strong, diffuse nuclear 
SMARCA4 expression in Burkitt's lymphoma. 
Figure 3. 
    
A, Unclassified sex cord–stromal tumour; haematoxylin and eosin 
(H&E). B, Unclassified sex cord stromal tumour showing strong but 
heterogeneous SMARCA4 expression. C, Adult-type granulosa cell 
tumour; H&E. D, Adult-type granulosa cell tumour showing weak 
heterogeneous SMARCA4 expression. 
Discussion 
Inactivation of a member of the SWI/SNF chromatin 
remodelling complex, SMARCA4, has recently been identified 
as the defining molecular event in SCCOHT.[6-9] This complex 
modulates nucleosome structure, thereby regulating DNA–
protein interactions in processes such as transcription, 
replication, and repair.[23, 24] SMARCA4 mutations identified 
in SCCOHT are typically nonsense, small indels leading to 
frameshifts, or splice-site mutations, and rarely missense 
mutations.[6, 8, 9] These coding sequence mutations are often 
accompanied by LOH of the wild-type allele, and occur in a 
stable, diploid genome; in a subset of cases (up to one half in 
some studies), mutations affect the germline DNA.[6-9] Rare 
cases of SCCOHT lacking molecular and immunohistological 
evidence of SMARCA4 deficiency show alterations in 
SMARCB1, representing a mechanism of oncogenesis via 
alternative defects in the SWI/SNF complex. Of three such 
cases (retained SMARCA4 expression/loss of SMARCB1 
expression) described to date, two in which SMARCA4 was 
investigated lacked molecular alteration of this gene; one case 
showed a frameshift mutation in SMARCB1, whereas the other 
was wild type upon genetic analysis.[11] Overall, 96.1% 
(124/129) of SCCOHT cases have been found to show loss of 
expression of either SMARCA4 (121 cases) or SMARCB1 
(three cases). 
SCCOHT may rarely show retained SMARCA4 
staining 
There are five reported cases of purported SCCOHT with 
retained or equivocal SMARCA4 expression, and these are 
summarized in Table 5. In four of these cases, a mutation was 
identified in SMARCA4, confirming the diagnosis despite the 
retained protein expression. Two of these cases were in the 
previous publication by Witkowski et al.[9] One tumour showed 
weak staining with SMARCA4, and harboured a monoallelic 
splice-site mutation in SMARCA4, predicted to result in an 
exonic in-frame deletion, and there was no LOH on 
chromosome 19p. The second case was from a patient with a 
germline missense mutation, and the tumour also showed 
somatic LOH; interestingly, her daughter, with the same 
germline mutation, had an SCCOHT with a somatic frameshift 
mutation, but this showed loss of SMARCA4 staining. These 
resembled other SCCOHT cases histologically. In the study by 
Jelinic et al., a splice-site mutation in SMARCA4 was identified 
in the case with equivocal protein expression.[6] In the other 
SCCOHT case with intact SMARCA4 expression in that study, 
the tumour harboured a homozygous in-frame deletion affecting 
amino acids of the helicase domain, postulated to result in a 
truncated inactive protein. The fifth case lacked molecular 
alterations in either SMARCA4 or SMARCB1, and showed 
retained expression of both proteins. These findings raise the 
possibility of misdiagnosis, but could also indicate a novel 
mechanism of oncogenesis in SCCOHT.[8] 
Table 5. Summary of reported small-cell carcinoma of the 
ovary, hypercalcaemic type cases with retained/equivocal 
SMARCA4 expression 
In light of these rare cases, if a morphological diagnosis of 
SCCOHT is favoured, and both SMARCA4 expression and 
SMARCB1 expression are intact, molecular testing of 
SMARCA4 may be indicated. However, given the rarity of this 
finding, when there is retained immunohistochemical 
expression of SMARCA4, other tumours in the differential 
diagnosis should be strongly considered. 
In ovarian neoplasms, loss of SMARCA4 expression 
is contextually specific to SCCOHT 
SCCOHT is the prototypical ovarian neoplasm composed 
predominantly or exclusively of small round cells with scant 
cytoplasm (so-called ‘small round blue cell tumour’). The 
differential diagnosis of such neoplasms is wide, and 
pathologists commonly struggle with these cases, owing to their 
overlapping morphological and immunohistochemical 
features.[3, 5] Many of these tumours occur in young women, 
are highly aggressive, and require specific chemotherapeutic 
agents, making a correct diagnosis imperative. In diagnosing 
the various tumour types, immunohistochemistry, as well as 
molecular studies, may be of value. Although typical SCCOHT 
is part of the differential diagnosis of a small round blue cell 
tumour, the large-cell variant of SCCOHT may be confused 
with a variety of neoplasms composed of large cells, such as 
undifferentiated carcinoma, large-cell neuroendocrine 
carcinoma, and malignant melanoma. The results of the current 
and prior studies indicate that loss of SMARCA4 expression is 
a highly sensitive and specific immunohistochemical marker of 
SCCOHT. Of the ~3600 cases of non-SCCOHT ovarian, 
uterine and non-gynaecological tumours studied to date 
(Tables 2 and 3), only a few cases have been noted to lack 
expression of SMARCA4: one case of uterine endometrioid 
carcinoma (1/360; <1%); 16 cases of endometrial 
dedifferentiated/undifferentiated carcinoma (16/59; 27%); four 
cases of uterine endometrial stromal sarcoma (4/53; 7.5%); one 
melanoma metastatic to ovary of the 47 primary or metastatic 
melanomas tested (1/47; 2.1%); and 17 ovarian clear-cell 
carcinomas (17/447; 3.8%), although these tumours are not 
typically considered in the differential diagnosis of SCCOHT.[8-
10, 14, 17-22] 
Although a single case of uterine endometrioid carcinoma was 
found to lack SMARCA4 expression, this has not been 
demonstrated in any of the 343 cases of ovarian endometrioid 
carcinoma examined.[9, 10, 17] 
Only a single case of primary ovarian endometrial stromal 
sarcoma has been studied, and it was found to retain 
SMARCA4 expression, but further work is warranted, as 7.5% 
of uterine endometrial stromal sarcomas show loss of 
SMARCA4 expression.[10] Finally, 16 of 59 (27%) endometrial 
dedifferentiated/undifferentiated carcinomas showed loss of 
SMARCA4 expression, but, of the 22 cases of ovarian 
undifferentiated/dedifferentiated carcinoma examined to date, 
only one has shown loss of SMARCA4 expression, and in this 
case it was noted in the undifferentiated component.[9, 10, 22] 
Another useful marker for SCCOHT is SMARCA2, a mutually 
exclusive SWI/SNF ATPase. Karnezis et al. recently 
demonstrated dual loss of SMARCA4 and SMARCA2 
expression in 42 SCCOHT cases, and dual loss of SMARCB1 
and SMARCA2 expression in two cases.[10] None of the 
ovarian clear-cell carcinomas showed dual loss of expression, 
suggesting this is specific for SCCOHT among primary ovarian 
tumours. In uterine tumours, however, dual loss of expression 
was noted in one case of dedifferentiated carcinoma and in two 
cases of high-grade endometrial stromal sarcoma.[10] In a 
similar study, Jelinic et al. showed dual loss of SMARCA4 and 
SMARCA2 expression in nine of 10 SCCOHT cases. Of the 
other 50 tumours stained (20 ovarian clear-cell carcinomas, 10 
ovarian granulosa cell tumours, 10 metastatic pulmonary small-
cell carcinomas, and 10 metastatic melanomas involving the 
ovary), none showed loss of expression of both markers, 
although loss of SMARCA4 expression was seen in one clear-
cell carcinoma and in one metastatic melanoma.[18] 
In our study, we included a large number of rare tumours that 
could present as morphological mimics of SCCOHT, including a 
wide array of small round blue cell tumours. Although some of 
these neoplasms have been included in prior studies, the 
number of cases examined has been relatively limited. Our 
data confirm that loss of SMARCA4 expression is highly 
sensitive and specific for SCCOHT. We demonstrate that a 
broad spectrum of tumours (Table 4), many of which are 
commonly considered in the differential diagnosis of SCCOHT, 
show intact SMARCA4 expression. Furthermore, in our study, 
SMARCB1 staining was also intact, except in cases of 
malignant rhabdoid tumour. 
Diagnosis of SCCOHT by SMARCA4 staining 
requires complete absence of staining and positive 
internal controls 
Although the majority of potential histological mimics showed 
diffuse, strong SMARCA4 expression, 28 (13%) cases showed 
focal expression in <30% of tumour cells. These cases 
generally showed weak-intensity to moderate-intensity staining, 
with a single case showing strong staining. This heterogeneous 
pattern of staining involved a number of tumour subtypes, and 
may be attributable to fixation issues in individual cases. 
However, the over-representation of certain tumour types, such 
as 50% (9/18) of fibromas/fibrothecomas, suggests that this is 
an intrinsic property of these particular neoplasms. Although 
fibromas/fibrothecomas do not enter into the differential 
diagnosis of SCCOHT, unclassified sex cord–stromal tumours 
may be considered, and 31% (4/13) of these neoplasms 
showed this heterogeneous pattern of staining. We 
acknowledge that TMAs may constitute a possible confounding 
factor, but, in the immunohistochemical study performed on full 
sections by Karanian-Philippe et al., a similar pattern of 
heterogeneity was noted in adult-type granulosa cell tumour 
(46% of 44 cases), desmoplastic small round-cell tumour (77% 
of nine cases), and Ewing's sarcoma (24% of 13 cases).[14] 
Thus, although loss of SMARCA4 expression is highly sensitive 
and specific for SCCOHT, accurate diagnosis requires a 
complete absence of staining in tumour cells with intact positive 
internal controls. The possible heterogeneity and the variable 
intensity of staining warrants caution in the interpretation of 
SMARCA4 staining, especially in small biopsy specimens. 
Conclusion 
Accurate histological classification of ovarian tumours is critical 
in ensuring appropriate patient management. Rare tumours 
such as SCCOHT may present diagnostic difficulty, owing to 
their rarity and, hence, unfamiliarity to many diagnostic 
pathologists, and their morphological overlap with other 
neoplasms. The current study confirms that loss of SMARCA4 
expression by immunohistochemistry is a sensitive and specific 
marker for SCCOHT, and, in the vast majority of cases, should 
resolve any diagnostic dilemmas. However, a number of 
caveats must be borne in mind. Accurate diagnosis of 
SCCOHT requires a complete absence of staining of tumour 
cells with an intact positive internal control, as some 
morphological mimics can show heterogeneous weak staining. 
This is most pertinent in biopsy samples. A single case of 
metastatic melanoma (1/47, 2.1%) involving the ovary has been 
demonstrated to show loss of SMARCA4 expression, and, in 
such cases, retained staining of SMARCA2 may be used to 
exclude SCCOHT.[17, 18] 
Furthermore, on the basis of the current data, if the 
morphological suspicion of SCCOHT is high and SMARCA4 
expression is intact, immunohistochemical testing for 
SMARCB1 should be performed. In the event of retained 
expression of both markers, an alternative diagnosis should be 
strongly considered, and an expanded panel of 
immunomarkers should be used to exclude entities in the 
differential diagnosis. As mutation-positive cases may rarely 
show retained protein expression, molecular testing may be 
required as the final arbiter. 
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